Background/Aims: To evaluate the efficacy of photodynamic therapy (PDT) combined with intravitreal injection of anti-vascular-endothelial-growth-factor (anti-VEGF) antibody in patients with polypoidal choroidal vasculopathy (PCV). Methods: Twenty-two eyes of 22 patients with PCV followed for 12 months after combination therapy with PDT and anti-VEGF were retrospectively reviewed. Patients received intravitreal anti-VEGF (1.25 mg bevacizumab or 0.5 mg ranibizumab) within 7 days after PDT. Retreatment with PDT and intravitreal anti-VEGF injections, or with intravitreal anti-VEGF alone, was performed when indicated. The main outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT). Results: Mean logMAR BCVA was 0.43 at baseline and 0.45, 0.36, 0.30 and 0.28 at 1, 3, 6 and 12 months, respectively, after the initial combination therapy. Mean BCVA was significantly improved at 6 and 12 months after treatment (p < 0.05). Mean CFT was 269.4 µm at baseline and 180.1, 136.7, 127.5 and 139.6 µm at 1, 3, 6 and 12 months, respectively, after the initial combination therapy. CFT decreased significantly throughout the follow-up period. At 12 months, mean BCVA improved by 1.5 lines, and mean CFT decreased by 129.8 µm. Polypoidal lesions disappeared in 7 of the 13 eyes in which indocyanine green angiography was performed at 12 months. No changes in the branching vascular network were observed in any of these 13 eyes. Patients were treated with PDT a mean of 1.3 times and injected with intravitreal anti-VEGF a mean of 3.4 times over the 12-month period. Conclusion: Combined PDT and intravitreal anti-VEGF may improve visual acuity and decrease CFT at 12 months. Large long-term prospective studies are needed to evaluate the efficacy and safety of combination therapy.

Keywords:
Vascular endothelial growth factor antibody, Polypoidal choroidal vasculopathy, Photodynamic therapy
1.
Yannuzzi LA, Sorenson J, Spaide RF, Lipson B: Idiopathic polypoidal choroidal vasculopathy. Retina 1990;10:1–8.
2.
Yannuzzi LA, Ciardella A, Spaide RF, et al: The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 1997;115:478–485.
3.
Schneider U, Gelisken F, Kreissig I: Indocyanine green angiography and idiopathic polypoidal choroidal vasculopathy. Br J Ophthalmol 1998;82:98–99.
4.
Moorthy RS, Lyon AT, Rabb MF, et al: Idiopathic polypoidal choroidal vasculopathy of the macula. Ophthalmology 1998;105:1380–1385.
5.
Uyama M, Wada M, Nagai Y, et al: Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 2002;133:639–648.
6.
Kwok AK, Lai TY, Chan CW, et al: Polypoidal choroidal vasculopathy in Chinese patients. Br J Ophthalmol 2002;133:639–648.
7.
Sho K, Takahashi K, Yamada H, et al: Polypoidal choroidal vasculopathy: incidence, dermographic features, and clinical characteristics. Arch Ophthalmol 2003;121:1392–1396.
8.
Yuzawa M, Mori R, Haruyama M: A study of laser photocoagulation for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2003;47:379–384.
9.
Nishijima K, Takahashi M, Akita J, et al: Laser photocoagulation of indocyanine green angiographically identified feeder vessels to idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 2004;137:770–773.
10.
Vedantham V, Kolluru C, Ramasamy K: Treatment of polypoidal choroidal vasculopathy with transpupillary thermotherapy: an interventional case report. Eye 2005;19:915–917.
11.
Okubo A, Ito M, Kamisasanuki T, Sakamoto T: Visual improvement following trans-Tenon’s retrobulbar triamcinolone acetonide infusion for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 2005;243:837–839.
12.
Terasaki H, Miyake Y, Suzuki T, et al: Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation. Br J Ophthalmol 2002;86:321–327.
13.
Shiraga F, Matsuo T, Yokoe S, et al: Surgical treatment of submacular hemorrhage associated with idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 1999;128:147–154.
14.
Silva RM, Figueira J, Cachulo ML, et al: Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 2005;243:973–979.
15.
Chan WM, Lam DS, Lai TY, et al: Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 2004;111:1576–1584.
16.
Gomi F, Ohji M, Sayanagi K, et al: One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008;115:141–146.
17.
Matsuoka M, Ogata N, Otsuji T, et al: Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 2004;88:809–815.
18.
Tong JP, Chan WM, Liu DT, et al: Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006;141:456–462.
19.
Fong DS, Custis P, Howes J, Hsu JW: Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: a multicenter, retrospective study. Ophthalmology 2010;117:298–302.
20.
Gomi F, Sawa M, Sakaguchi H, et al: Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:70–73.
21.
Lai TY, Chan WM, Liu DTL, et al: Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:661–666.
22.
Song JH, Byeon SH, Lee SC, et al: Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy. Ophthalmologica 2009;223:85–92.
23.
Spaide RF, Donsoff I, Lam DL, et al: Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 2002;22:529–535.
24.
Kurashige Y, Otani A, Sasahara M, et al: Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2008;146:513–519.
25.
Heier JS, Boyer DS, Ciulla TA, et al, FOCUS study group: Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol 2006;124:1532–1542.
26.
Dhalla MS, Shah GK, Blinder KJ, et al: Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26:988–993.
27.
Lazic R, Gabric N: Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179–1185.
28.
Costa RA, Jorge R, Calucci D, et al: Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 2007;245:1273–1280.
29.
Kaiser PK; for the Registry of Visudyne AMD Therapy Writing Committee: Verteprofin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2009;116:747–755.
30.
Sato T, Kishi S, Matsumoto H, Mukai R: Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol 2010;149:947–954.
31.
Ruamviboonsuk P, Tadarati M, Vanichvaranont S, et al: Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study. Br J Ophthalmol 2010;94:1045–1051.
32.
Bressler NM: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329–1345.
33.
Lee SY, Kim JG, Joe SG, et al: The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy. Korean J Ophthalmol 2008;22:92–99.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.